13 results about "Ventricular fibrillation" patented technology

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

The present disclosure relates to compositions and methods, including prodrugs of (S)-sec-butyl 2-(3-(4-(2- (diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, ventricular arrhythmias, or ventricular fibrillation.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Cardiac Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the heart. Also disclosed are subsequent generations of this Cardiac Targeting Peptide with improved, higher efficiency of cardiac uptake for CTP-mediated delivery of antiarrhythmics subjects for treating Atrial fibrillation or Ventricular fibrillation, CTP-mediated delivery of neuregulin-1β for treating systolic heart failure (SHF), and Szeto-Schiller peptides for treatment of diastolic congestive heart failure, among other applications.

The application provides a heart valve balloon dilatation catheter applied to the technical field of medical devices, which comprises a balloon, a protection net, a support net, an inner tube, an outer tube, a connecting structure and a head end structure; the protection net is wrapped on the outer surface of the balloon, the protection net is provided with a supporting leg, the support net is fixedly surrounded on the outer surface of the protection net through the supporting leg, and a target interval is formed between the support net and the protection net; the first end of the balloon is fixedly connected with the head end structure, the second end of the balloon is fixedly connected with the first end of the outer tube, the second end of the outer tube is fixedly connected with the connecting structure, the inner tube extends through the inside of the balloon, the first end of the inner tube is connected with the head end structure, the second end of the inner tube is fixedly connected with the connecting structure, and the outer tube is wrapped on the outer surface of the inner tube.In the heart valve balloon dilatation catheter, the target interval can provide a blood flow space, so that the blood can flow smoothly, the risk of ventricular fibrillation and cardiac arrest is reduced, and therefore the safety of heart surgery can be improved.

The invention provides an asymmetrically flexible cardiac mapping catheter that includes a deformation mechanism by which a user may deform a distal portion of the catheter giving the user the ability to reach, and map electrical activity of, substantially any surface within the heart.

The utility model provides a pulse ablation system. The pulse ablation system comprises a medical catheter, a pulse generator, a three-dimensional mapping part and a controller, the medical catheter comprises a catheter body and an electrode assembly. The electrode assembly comprises a head electrode and a ring electrode; the head electrode is arranged at the far end of the catheter body, and the multiple ring electrodes are arranged on the far end side face of the catheter body in a sleeving mode at intervals. The pulse generator is electrically connected with the electrode assembly; the three-dimensional mapping part is in communication connection with the ring electrode; and the controller is in communication connection with the pulse generator and the three-dimensional mapping part. When the pulse ablation system is used for executing a pulse ablation operation, an electrocardiosignal can be obtained by the ring electrode, the electrocardiosignal is received by the three-dimensional mapping part and processed into an electrocardiogram, and then the controller can control the pulse generator to generate a pulse according to the electrocardiogram, so that the application time of pulse energy is proper; therefore, ventricular fibrillation is reduced or even avoided.

A system for VT localization comprises an electrocardiograph (ECG) device for detecting electrical signals of a ventricular fibrillation event in a patient and producing ECG data, a localizer, and a display device. The localizer comprises a memory and a processor, the memory storing a model and one or more parameters of the model. The memory further stores instructions that when executed by the processor cause the processor to receive the ECG data, and generate a determination indicating whether a detected VT signal arose from an endocardial surface or epicardial surface based on signal averaged waveform for each of the leads. The display device is configured to output the determination, which can also be communicated to follow-on provider systems.

The application provides a cardiac arrest rescue device and method, wherein the device comprises a first current output module, a second current output module and a pulse switching control module; the pulse switching control module controls the size and wave phase of the current delivered to the output electrode module by the first current output module and the second current output module according to input control signals and output feedback signals, so as to control the output electrode module to switch the output of a cardiopulmonary resuscitation pulse, a ventricular fibrillation induction pulse or a cardiac defibrillation pulse. The cardiac arrest rescue device and method of the application can effectively avoid the risk of trauma caused to the human body during mechanical device rescue, do not require additional auxiliary devices, are simple to operate, effectively shorten the first-aid time and improve the rescue success rate.

The invention provides an intracardiac sound signal identification and classification method based on a deep learning architecture, and the method comprises the steps: obtaining an original intracardiac sound signal, and carrying out the filtering and noise reduction of the signal; performing short-time Fourier transform on single heartbeat signal data, and converting the single heartbeat signal data into a spectrogram of heartbeat signals; constructing a cyclic convolution residual network model, inputting the training set into the model for training, performing short-time Fourier transform on heartbeat signals in a test set needing to be identified, and generating a spectrogram required by the network model; the spectrogram of the heartbeat signals is input into the trained cyclic convolution residual network model, the model analyzes the spectrogram, and an atrial fibrillation or ventricular fibrillation recognition result is output; and executing the step on all data in the test set to obtain an atrial fibrillation or ventricular fibrillation identification result of each heartbeat signal.

The invention belongs to the field of medicines, and relates to a benzenesulfonamide compound as well as a preparation method and application thereof. The invention discloses a benzenesulfonamide compound as shown in a general formula (I) and a preparation method and application thereof. The series of compounds provided by the invention can be used as lead compounds of sodium ion channel inhibitors, and are expected to be used for preparing medicines for treating arrhythmia, including premature beat, acute and recurrent atrial fibrillation, heart failure, supraventricular tachyarrhythmia (PVC), ventricular premature contraction (PVC), ventricular tachycardia (VT) or ventricular fibrillation (VF).

The invention belongs to the technical field of medicine and food homology, and particularly relates to a medicine and food homology composition based on rhizoma polygonati and a preparation method of the medicine and food homology composition. The rhizoma polygonati-based medicinal and edible composition is prepared from the following raw materials: rhizoma polygonati, radix astragali, fructus corni, radix codonopsis, fructus gardeniae and radix puerariae. The traditional Chinese medicine theory is used as guidance, genuine medicinal materials are selected, and the six medicinal materials are combined for use, so that the effects of tonifying yin and yang, tonifying qi and blood, tonifying qi, raising yang, promoting salivation, nourishing blood, tonifying spleen, moistening lung and tonifying liver and kidney are achieved, and the bitter cold property of gardenia is neutralized. Animal experiments show that the medicinal and edible composition can obviously prolong the occurrence time of VP, VT and VF, reduce the occurrence rate of ventricular fibrillation and effectively treat arrhythmia. Compared with the prior art, the medicinal and edible composition is remarkable in clinical curative effect, small in toxic and side effects and suitable for being taken for a long time, and has good social benefits and economic benefits.

The invention relates to the technical field of electrocardiogram analysis, in particular to a method and system for predicting ventricular fibrillation, and the method comprises the steps: obtaining long-time electrocardiogram data of a first preset time length, calculating characteristic parameters and average heart rate of the long-time electrocardiogram data, fitting each characteristic parameter and the average heart rate, and obtaining a characteristic curve corresponding to each characteristic parameter; the method comprises the following steps: acquiring short-time electrocardiogram data of a preset monitoring time length, calculating characteristic parameters and an average heart rate of the short-time electrocardiogram data, calling a characteristic curve of each characteristic parameter, correcting the characteristic parameters of the short-time electrocardiogram data in combination with the average heart rate of the short-time electrocardiogram data, and acquiring standardized characteristic parameters; and inputting the standardized characteristic parameters into the constructed prediction model, and predicting the risk probability of the occurrence of the ventricular fibrillation. According to the scheme, the accuracy of ventricular fibrillation prediction can be improved, and high-risk groups can be helped to carry out early warning on the sudden cardiac arrest risk of the high-risk groups.

An example method includes identifying a first segment of an electrocardiogram (ECG) that ends prior to administration of an electrical shock and identifying at least one second segment of the ECG that begins after the administration of the electrical shock. The example method further includes predicting, based on the first segment and the at least one second segment, that the ECG is indicative of a defibrillation-resistant heart rhythm. The first segment is converted into a first scalogram, and the at least one segment is converted into at least one second scalogram. The defibrillation-resistant heart rhythm is predicted based on comparisons between the scalograms and the eigenscalograms. An indication of the predicted defibrillation-resistant heart rhythm is output.